Research | Assessing pharma companies’ response to COVID-19 and the threat of future pandemics
Assessing pharma companies’ response to COVID-19 and the threat of future pandemics

Assessing pharma companies’ response to COVID-19 and the threat of future pandemics

18 November 2022

This report analyses pharmaceutical companies’ response during the initial stage of the COVID-19 pandemic, their performance in terms of registration and applying equitable access strategies for COVID-19 vaccines, voluntary licensing agreements and technology transfers, and forward-looking assessment of their preparedness for future epidemics and pandemics.

 

Please login or join for free to read more.